Provided herein are methods of treating a subject who has a synucleinopathy (e.g., Parkinson's disease) that include: administering to a subject in need of such treatment therapeutically effective amounts of a β2-adrenoreceptor agonist and at least one therapeutic agent selected from the group consisting of: a synucleinopathy therapeutic agent, a β2-adrenoreceptor antagonist and a health supplement, wherein the health supplement is selected from the group consisting of caffeine, inosine, creatine, coenzyme Q10, vitamin E, and omega-3 fatty acids, to thereby treat Parkinson's disease in the subject.
COMBINATIONS INCLUDING BETA-ADRENORECEPTOR AGONISTS FOR TREATMENT OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS